Evidence map›Paper›PMID 28829762›Full record

ArticleBritish journal of cancer2017

Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes.

Javier Gayarre, Paloma Martín-Gimeno, Ana Osorio, Beatriz Paumard, Alicia Barroso, Victoria Fernández, Miguel de la Hoya, Alejandro Rojo, Trinidad Caldés, José Palacios and 3 more

Abstract read
In one paragraph

Article in British journal of cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Homologous recombination-deficient mutation cluster in tumor suppressorProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  7. Article
  8. Article
  9. BeyondJournal of clinical medicine · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Javier GayarreHuman Genetics Group, Spanish National Cancer Research Center, C/Melchor Fernández Almagro 3, Madrid 28029, Spain.
Paloma Martín-GimenoHuman Genetics Group, Spanish National Cancer Research Center, C/Melchor Fernández Almagro 3, Madrid 28029, Spain.
Ana OsorioHuman Genetics Group, Spanish National Cancer Research Center, C/Melchor Fernández Almagro 3, Madrid 28029, Spain.
Beatriz PaumardHuman Genetics Group, Spanish National Cancer Research Center, C/Melchor Fernández Almagro 3, Madrid 28029, Spain.
Alicia BarrosoHuman Genetics Group, Spanish National Cancer Research Center, C/Melchor Fernández Almagro 3, Madrid 28029, Spain.
Victoria FernándezHuman Genetics Group, Spanish National Cancer Research Center, C/Melchor Fernández Almagro 3, Madrid 28029, Spain.
Miguel de la HoyaLaboratorio de Oncología Molecular, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital San Carlos (IdISSC), Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid 28040, Spain.
Alejandro RojoHospital MD Anderson Cancer Centre, Madrid 28033, Spain.
Trinidad CaldésLaboratorio de Oncología Molecular, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital San Carlos (IdISSC), Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Madrid 28040, Spain.
José PalaciosServicio de Anatomía Patológica. Hospital Universitario Ramón y Cajal (IRYCIS), Departamento de Medicina y Especialidades Médicas, Universidad de Alcalá, Madrid 28034, Spain.
Miguel UriosteBiomedical Network Research Centre on Rare Diseases (CIBERER), Madrid 28029, Spain.
Javier BenítezHuman Genetics Group, Spanish National Cancer Research Center, C/Melchor Fernández Almagro 3, Madrid 28029, Spain.
María J GarcíaHuman Genetics Group, Spanish National Cancer Research Center, C/Melchor Fernández Almagro 3, Madrid 28029, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite a high prevalence of deleterious missense variants, most studies of RAD51C ovarian cancer susceptibility gene only provide in silico pathogenicity predictions of missense changes. We identified a novel deleterious RAD51C missense variant (p.Arg312Trp) in a high-risk family, and propose a criteria to prioritise RAD51C missense changes qualifying for functional analysis.

methodsTo evaluate pathogenicity of p.Arg312Trp variant we used sequence homology, loss of heterozygosity (LOH) and segregation analysis, and a comprehensive functional characterisation. To define a functional-analysis prioritisation criteria, we used outputs for the known functionally confirmed deleterious and benign RAD51C missense changes from nine pathogenicity prediction algorithms.

resultsThe p.Arg312Trp variant failed to correct mitomycin and olaparib hypersensitivity and to complement abnormal RAD51C foci formation according to functional assays, which altogether with LOH and segregation data demonstrated deleteriousness. Prioritisation criteria were based on the number of predictors providing a deleterious output, with a minimum of 5 to qualify for testing and a PredictProtein score greater than 33 to assign high-priority indication.

conclusionsOur study points to a non-negligible number of RAD51C missense variants likely to impair protein function, provides a guideline to prioritise and encourage their selection for functional analysis and anticipates that reference laboratories should have available resources to conduct such assays.

Indexed as

AdultAgedAged, 80 and overAlgorithmsBreast NeoplasmsCarcinomaCase-Control StudiesCell CycleCells, CulturedCell SurvivalChromosomal InstabilityColorectal NeoplasmsDNA-Binding ProteinsDNA Mutational AnalysisExomeFemaleDNA-Binding ProteinsH2AX protein, humanHistonesMitomycinRAD51C protein, human

Identifiers

PMID28829762
PMCPMC5625680

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.